Intest Res.  2017 Apr;15(2):147-148. 10.5217/ir.2017.15.2.147.

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?

• Im JP

• KMID: 2425154
• DOI: http://doi.org/10.5217/ir.2017.15.2.147

Abstract

No abstract available.

MeSH Terms

Adalimumab*
Crohn Disease*
Fistula*
Infliximab*
Adalimumab
Infliximab

Reference

1. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016; 14:111–119. PMID: 27175111.

2. Lee HA, Suk JY, Choi SY, et al. Characteristics of pediatric inflammatory bowel disease in Korea: comparison with EUROKIDS data. Gut Liver. 2015; 9:756–760. PMID: 25963086.

3. Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut. 2014; 63:1381–1392. PMID: 24951257.

4. Park JJ, Yang SK, Ye BD, et al. Second Korean guidelines for the management of Crohn's disease. Intest Res. 2017; 15:38–67. PMID: 28239314.

5. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999; 340:1398–1405. PMID: 10228190.

6. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350:876–885. PMID: 14985485.

7. Schwartz DA, Ghazi LJ, Regueiro M. Guidelines for medical treatment of Crohn's perianal fistulas: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2015; 21:737–752. PMID: 25751068.

8. Doecke JD, Hartnell F, Bampton P, et al. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. Aliment Pharmacol Ther. 2017; 45:542–552. PMID: 27995633.

9. Ji CC, Takano S. Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease. Intest Res. 2017; 15:182–186.

10. Lee KM, Kim YS, Seo GS, Kim TO, Yang SK. IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Use of thiopurines in inflammatory bowel disease: a consensus statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015; 13:193–207. PMID: 26130993.